Meier Christoph A, Chicheportiche Rachel, Juge-Aubry Cristiana E, Dreyer Magali G, Dayer Jean-Michel
Division of Endocrinology and Diabetes, Department of Internal Medicine, University hospital, CH-1211, Geneva 14, Switzerland.
Cytokine. 2002 Jun 21;18(6):320-8. doi: 10.1006/cyto.2002.1945.
Monocytes/macrophages (Mphi) play a pivotal role in the persistence of chronic inflammation and local tissue destruction in diseases such as rheumatoid arthritis and atherosclerosis. The production by Mphi of cytokines, chemokines, metalloproteinases and their inhibitors is an essential component in this process, which is tightly regulated by multiple factors. The peroxisome proliferator-activated receptors (PPARs) were shown to be involved in modulating inflammation. PPARgamma is activated by a wide variety of ligands such as fatty acids, the anti-diabetic thiazolidinediones (TZDs), and also by certain prostaglandins of which 15-deoxy-Delta(12,14)-PGJ2 (PGJ2). High concentrations of PPARgamma ligands were shown to have anti-inflammatory activities by inhibiting the secretion of interleukin-1 (IL-1), interleukin-6 (IL-6) and tumour necrosis factor alpha (TNFalpha) by stimulated monocytes. The aim of this study was to determine whether PGJ2 and TZDs would also exert an immunomodulatory action through the up-regulation of anti-inflammatory cytokines such as the IL-1 receptor antagonist (IL-1Ra). THP-1 monocytic cells were stimulated with PMA, thereby enhancing the secretion of IL-1, IL-6, TNFalpha, IL-1Ra and metalloproteinases. Addition of PGJ2 had an inhibitory effect on IL-1, IL-6 and TNFalpha secretion, while increasing IL-1Ra production. In contrast, the bona fide PPARgamma ligands (TZDs; rosiglitazone, pioglitazone and troglitazone) barely inhibited proinflammatory cytokines, but strongly enhanced the production of IL-1Ra from PMA-stimulated THP-1 cells. Unstimulated cells did not respond to TZDs in terms of IL-1Ra production, suggesting that in order to be effective, PPAR ligands depend on PMA signalling. Basal levels of PPARgamma are barely detectable in unstimulated THP-1 cells, while stimulation with PMA up-regulates its expression, suggesting that higher levels of PPARgamma expression are necessary for receptor ligand effects to occur. In conclusion, we demonstrate for the first time that TZDs may exert an anti-inflammatory activity by inducing the production of the IL-1Ra.
单核细胞/巨噬细胞(Mphi)在类风湿性关节炎和动脉粥样硬化等疾病的慢性炎症持续存在及局部组织破坏过程中起关键作用。Mphi产生细胞因子、趋化因子、金属蛋白酶及其抑制剂是这一过程的重要组成部分,该过程受到多种因素的严格调控。过氧化物酶体增殖物激活受体(PPARs)被证明参与调节炎症。PPARγ可被多种配体激活,如脂肪酸、抗糖尿病噻唑烷二酮类(TZDs),以及某些前列腺素,其中包括15-脱氧-Δ(12,14)-前列腺素J2(PGJ2)。高浓度的PPARγ配体通过抑制受刺激单核细胞分泌白细胞介素-1(IL-1)、白细胞介素-6(IL-6)和肿瘤坏死因子α(TNFα)而具有抗炎活性。本研究的目的是确定PGJ2和TZDs是否也会通过上调抗炎细胞因子如IL-1受体拮抗剂(IL-1Ra)来发挥免疫调节作用。用佛波酯(PMA)刺激THP-1单核细胞,从而增强IL-1、IL-6、TNFα、IL-1Ra和金属蛋白酶的分泌。添加PGJ2对IL-1、IL-6和TNFα的分泌有抑制作用,同时增加IL-1Ra的产生。相比之下,真正的PPARγ配体(TZDs;罗格列酮、吡格列酮和曲格列酮)几乎不抑制促炎细胞因子,但能强烈增强PMA刺激的THP-1细胞中IL-1Ra的产生。未受刺激的细胞在IL-1Ra产生方面对TZDs无反应,这表明PPAR配体要发挥作用依赖于PMA信号传导。在未受刺激的THP-1细胞中几乎检测不到PPARγ的基础水平,而PMA刺激可上调其表达,这表明较高水平的PPARγ表达是受体配体效应发生所必需的。总之,我们首次证明TZDs可能通过诱导IL-1Ra的产生发挥抗炎活性。